AGIO Agios Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGIO

Price (delayed)

$31.49

Market cap

$1.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.33

Enterprise value

$1.75B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
Agios Pharmaceuticals's gross profit has surged by 91% YoY and by 12% QoQ
The revenue has surged by 88% year-on-year and by 12% since the previous quarter
The quick ratio is down by 9% year-on-year but it is up by 3.3% since the previous quarter
Agios Pharmaceuticals's EPS has shrunk by 60% QoQ and by 50% YoY
AGIO's net income has shrunk by 60% QoQ and by 52% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agios.com
Peers: XNCR EXEL BMRN PFE

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
56.19M
Market cap
$1.77B
Enterprise value
$1.75B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.17
Price to sales (P/S)
65.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.37
Earnings
Revenue
$26.82M
EBIT
-$352.09M
EBITDA
-$334.75M
Free cash flow
-$295.74M
Per share
EPS
-$6.33
Free cash flow per share
-$5.31
Book value per share
$14.51
Revenue per share
$0.48
TBVPS
$16.84
Balance sheet
Total assets
$937.12M
Total liabilities
$126.1M
Debt
$72M
Equity
$811.02M
Working capital
$765.88M
Liquidity
Debt to equity
0.09
Current ratio
12.27
Quick ratio
11.47
Net debt/EBITDA
0.05
Margins
EBITDA margin
-1,248%
Gross margin
89.3%
Net margin
-1,312.6%
Operating margin
-1,459.5%
Efficiency
Return on assets
-33.7%
Return on equity
-38.1%
Return on invested capital
-35.9%
Return on capital employed
-40.5%
Return on sales
-1,312.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
-0.57%
1 week
6.64%
1 month
8.36%
1 year
42.49%
YTD
41.4%
QTD
7.69%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$26.82M
Gross profit
$23.94M
Operating income
-$391.49M
Net income
-$352.09M
Gross margin
89.3%
Net margin
-1,312.6%
Agios Pharmaceuticals's gross profit has surged by 91% YoY and by 12% QoQ
The revenue has surged by 88% year-on-year and by 12% since the previous quarter
AGIO's net income has shrunk by 60% QoQ and by 52% YoY
Agios Pharmaceuticals's operating income has plunged by 56% YoY and by 53% from the previous quarter

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.17
P/S
65.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.37
Agios Pharmaceuticals's EPS has shrunk by 60% QoQ and by 50% YoY
The P/B is 45% above the last 4 quarters average of 1.5 but 25% below the 5-year quarterly average of 2.9
Agios Pharmaceuticals's equity has decreased by 26% YoY and by 9% QoQ
The revenue has surged by 88% year-on-year and by 12% since the previous quarter
AGIO's P/S is 5% above its last 4 quarters average of 62.2

Efficiency

How efficient is Agios Pharmaceuticals business performance
AGIO's return on equity has dropped by 84% year-on-year and by 73% since the previous quarter
The company's return on invested capital has shrunk by 83% YoY and by 71% QoQ
The ROA has plunged by 82% YoY and by 72% from the previous quarter
Agios Pharmaceuticals's return on sales has decreased by 44% QoQ but it has increased by 19% YoY

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The total assets has declined by 24% year-on-year and by 7% since the previous quarter
The quick ratio is down by 9% year-on-year but it is up by 3.3% since the previous quarter
The debt is 91% smaller than the equity
Agios Pharmaceuticals's equity has decreased by 26% YoY and by 9% QoQ
The debt has declined by 16% year-on-year and by 4.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.